JP2022550915A5 - - Google Patents
Info
- Publication number
- JP2022550915A5 JP2022550915A5 JP2022520976A JP2022520976A JP2022550915A5 JP 2022550915 A5 JP2022550915 A5 JP 2022550915A5 JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022550915 A5 JP2022550915 A5 JP 2022550915A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- oligonucleotides
- c9orf72
- pharmaceutical composition
- repeat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133056A JP2025179843A (ja) | 2019-10-06 | 2025-08-08 | オリゴヌクレオチド組成物及びその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911340P | 2019-10-06 | 2019-10-06 | |
| US62/911,340 | 2019-10-06 | ||
| US202062983736P | 2020-03-01 | 2020-03-01 | |
| US62/983,736 | 2020-03-01 | ||
| PCT/US2020/032244 WO2020227691A2 (en) | 2019-05-09 | 2020-05-08 | Oligonucleotide compositions and methods of use thereof |
| USPCT/US2020/032244 | 2020-05-08 | ||
| US202063069704P | 2020-08-24 | 2020-08-24 | |
| US63/069,704 | 2020-08-24 | ||
| PCT/US2020/054307 WO2021071788A2 (en) | 2019-10-06 | 2020-10-05 | Oligonucleotide compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133056A Division JP2025179843A (ja) | 2019-10-06 | 2025-08-08 | オリゴヌクレオチド組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550915A JP2022550915A (ja) | 2022-12-05 |
| JP2022550915A5 true JP2022550915A5 (https=) | 2024-01-11 |
Family
ID=75438309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520976A Pending JP2022550915A (ja) | 2019-10-06 | 2020-10-05 | オリゴヌクレオチド組成物及びその使用方法 |
| JP2025133056A Pending JP2025179843A (ja) | 2019-10-06 | 2025-08-08 | オリゴヌクレオチド組成物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133056A Pending JP2025179843A (ja) | 2019-10-06 | 2025-08-08 | オリゴヌクレオチド組成物及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240175016A1 (https=) |
| EP (1) | EP4037695A4 (https=) |
| JP (2) | JP2022550915A (https=) |
| KR (1) | KR20220070324A (https=) |
| CN (1) | CN114585370A (https=) |
| AU (1) | AU2020363344A1 (https=) |
| BR (1) | BR112022006207A2 (https=) |
| CA (1) | CA3156176A1 (https=) |
| IL (1) | IL291974A (https=) |
| MX (1) | MX2022004102A (https=) |
| TW (1) | TW202126810A (https=) |
| WO (1) | WO2021071788A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| CN108779132B (zh) | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2942515C (en) * | 2014-03-18 | 2025-12-09 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| RS60230B1 (sr) * | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| IL295755A (en) * | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| WO2017079291A1 (en) * | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| EP3664816A4 (en) * | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| EP3965780A4 (en) * | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
-
2020
- 2020-10-05 JP JP2022520976A patent/JP2022550915A/ja active Pending
- 2020-10-05 KR KR1020227015125A patent/KR20220070324A/ko not_active Withdrawn
- 2020-10-05 IL IL291974A patent/IL291974A/en unknown
- 2020-10-05 EP EP20875598.3A patent/EP4037695A4/en active Pending
- 2020-10-05 US US17/766,680 patent/US20240175016A1/en active Pending
- 2020-10-05 CN CN202080069266.5A patent/CN114585370A/zh active Pending
- 2020-10-05 BR BR112022006207A patent/BR112022006207A2/pt not_active Application Discontinuation
- 2020-10-05 CA CA3156176A patent/CA3156176A1/en active Pending
- 2020-10-05 WO PCT/US2020/054307 patent/WO2021071788A2/en not_active Ceased
- 2020-10-05 AU AU2020363344A patent/AU2020363344A1/en not_active Abandoned
- 2020-10-05 MX MX2022004102A patent/MX2022004102A/es unknown
- 2020-10-06 TW TW109134610A patent/TW202126810A/zh unknown
-
2025
- 2025-08-08 JP JP2025133056A patent/JP2025179843A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550915A5 (https=) | ||
| JP2022532169A5 (https=) | ||
| JP2020534253A5 (https=) | ||
| JP2023548584A5 (https=) | ||
| JP2025165976A5 (https=) | ||
| JP2024009824A5 (https=) | ||
| JP2023145620A5 (https=) | ||
| US20220098585A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP2009532392A5 (https=) | ||
| CA3156176A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| JP2021512629A5 (https=) | ||
| CA3139513A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| JP2018525357A5 (https=) | ||
| JP2022551124A5 (https=) | ||
| JP2020522265A5 (https=) | ||
| JP2023078293A5 (https=) | ||
| JP2021007391A5 (https=) | ||
| JP2018513682A5 (https=) | ||
| JP2022517783A (ja) | 活性剤の脂質ナノ粒子送達のための脂質 | |
| CA3137740A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2014527401A5 (https=) | ||
| JP2024536088A5 (https=) | ||
| JP2015511494A5 (https=) | ||
| WO1995017507A1 (en) | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE |